News
VALN
24.41
+2.49%
0.59
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 2d ago
Valneva completes lot-to-lot consistency trial for one-shot chikungunya vaccine
Valneva (NASDAQ:VALN) said it successfully completed a lot-to-lot phase 3 trial of its single-shot chikungunya vaccine VLA1553. The company said the final analysis included six-month follow-up data and confirmed the results
Seekingalpha · 2d ago
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
Saint Herblain (France), May 25, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The fi...
GlobeNewswire · 2d ago
Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
Zacks · 05/20 16:53
Valneva says the European Medicines Agency accepted the application for its COVID-19 vaccine
U.S.-listed shares of Valneva SE jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its COVID-19 vaccine candidate. If the experimental shot receives a positive recommenda...
marketwatch.com · 05/19 12:36
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/19 12:01
Valneva stock rises as EMA accepts COVID vaccine filing, panel to begin review
Valneva (NASDAQ:VALN) (OTCPK:INRLF) said the European Medicines Agency (EMA) accepted its marketing authorization application (MAA) for COVID-19 vaccine VLA2001. The French company's stock rose ~9% to €10.94 on May 19 on
Seekingalpha · 05/19 08:40
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
Saint Herblain (France), May 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization application (MAA) for Valne...
GlobeNewswire · 05/19 05:00
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal
Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.
Zacks · 05/17 18:10
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
Hot Stocks: Energy stocks rally; YOU jumps on earnings; MANT takeover deal; CMRX drops 60%; VALN hits low
Wall Street finished with a mixed performance on Monday, as the major averages wound their way through another uncertain session. The S&P 500 and Nasdaq lost ground, while the Dow
Seekingalpha · 05/16 21:54
EU Says Final Decision Yet To Be Taken On Terminating Valneva COVID-19 Vaccine Deal
The European Commission said that no final decision had been made about the possible termination of a contract with Valneva SE (NASDAQ: VALN) to supply its COVID-19 vaccine to the European Union.
Benzinga · 05/16 18:15
XERS, AGRX and LHDX among mid-day movers
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon
Seekingalpha · 05/16 16:31
Harpoon Therapeutics, Grove top healthcare gainers; Chimerix, Eliem lead losers' pack
Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides (NNVC) +11%. Travere Therapeutics (TVTX) +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix (CMRX) -58%. Eliem Therapeutics (ELYM) -29%. Humacyte (HUMA) -20%. Valneva (VALN) -2...
Seekingalpha · 05/16 14:03
Why Valneva's Shares Are Plunging Today Premarket
Benzinga · 05/16 13:08
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/16 12:16
Wall Street Wavers Pre-Bell as Weak China Data Dent Sentiment
MT Newswires · 05/16 09:35
Valneva COVID vaccine VLA2001 gets emergency use nod in UAE but EU intentions send stock spiralling down
Valneva (OTCPK:INRLF) (NASDAQ:VALN) said the United Arab Emirates (UAE) granted emergency use authorization to its inactivated, adjuvanted COVID-19 vaccine VLA2001. However, the French company's stock fell ~20% to €9.50 on May
Seekingalpha · 05/16 09:20
Valneva stock slumps ~20% as EU plans to terminate COVID-19 vaccine deal
Valneva (NASDAQ:VALN) (OTCPK:INRLF) said the European Commission (EC) intends to terminate its advance purchase agreement (APA) for the company's inactivated whole-virus COVID-19 vaccine VLA2001. The French company's stock fell ~20% to €9.50 on
Seekingalpha · 05/16 08:49
Top Premarket Decliners
MT Newswires · 05/16 08:13
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.